Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) on Monday, plunged -6.11% from the previous trading day, before settling in for the closing price of $4.58. Within the past 52 weeks, MRVI’s price has moved between $4.28 and $11.56.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 55.75% over the past five years. The company achieved an average annual earnings per share of -361.30%. With a float of $117.88 million, this company’s outstanding shares have now reached $141.59 million.
Let’s look at the performance matrix of the company that is accounted for 650 employees. In terms of profitability, gross margin is 43.66%, operating margin of -70.66%, and the pretax margin is 159.33%.
Maravai LifeSciences Holdings Inc (MRVI) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Maravai LifeSciences Holdings Inc is 16.90%, while institutional ownership is 87.32%. The most recent insider transaction that took place on Jan 31 ’25, was worth 125,750. In this transaction General Counsel of this company sold 25,000 shares at a rate of $5.03, taking the stock ownership to the 167,618 shares. Before that another transaction happened on Jan 31 ’25, when Company’s Officer proposed sale 25,000 for $5.03, making the entire transaction worth $125,750.
Maravai LifeSciences Holdings Inc (MRVI) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -361.30% per share during the next fiscal year.
Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) Trading Performance Indicators
Maravai LifeSciences Holdings Inc (MRVI) is currently performing well based on its current performance indicators. A quick ratio of 9.94 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.65, a number that is poised to hit -0.04 in the next quarter and is forecasted to reach -0.07 in one year’s time.
Technical Analysis of Maravai LifeSciences Holdings Inc (MRVI)
Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) saw its 5-day average volume 1.65 million, a negative change from its year-to-date volume of 2.0 million. As of the previous 9 days, the stock’s Stochastic %D was 7.68%. Additionally, its Average True Range was 0.41.
During the past 100 days, Maravai LifeSciences Holdings Inc’s (MRVI) raw stochastic average was set at 1.14%, which indicates a significant decrease from 3.31% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.60% in the past 14 days, which was lower than the 102.75% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.33, while its 200-day Moving Average is $7.52. Nevertheless, the first resistance level for the watch stands at $4.63 in the near term. At $4.97, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.16. If the price goes on to break the first support level at $4.10, it is likely to go to the next support level at $3.91. Assuming the price breaks the second support level, the third support level stands at $3.57.
Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) Key Stats
Market capitalization of the company is 1.09 billion based on 252,528K outstanding shares. Right now, sales total 288,950 K and income totals -119,030 K. The company made 65,200 K in profit during its latest quarter, and -99,040 K in sales during its previous quarter.
